Equillium Stock Forecast, Price & News

Equillium (NASDAQ:EQ) Frequently Asked Questions

Is Equillium a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Equillium stock.
View analyst ratings for Equillium or view top-rated stocks.

How has Equillium's stock been impacted by Coronavirus?

Equillium's stock was trading at $3.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EQ stock has increased by 41.1% and is now trading at $4.94.
View which stocks have been most impacted by COVID-19.

When is Equillium's next earnings date?

Equillium is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Equillium.

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) issued its earnings results on Wednesday, November, 10th. The company reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.01.
View Equillium's earnings history.

What price target have analysts set for EQ?

5 brokers have issued twelve-month target prices for Equillium's shares. Their forecasts range from $12.00 to $18.00. On average, they expect Equillium's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 193.5% from the stock's current price.
View analysts' price targets for Equillium or view top-rated stocks among Wall Street analysts.

Who are Equillium's key executives?

Equillium's management team includes the following people:

• Bruce D. Steel, President, Chief Executive Officer & Director
• Christine Zedelmayer, Chief Operating Officer & Senior Vice President
• Jason A. Keyes, Chief Financial Officer (LinkedIn Profile)
• Stephen Connelly, Director & Chief Scientific Officer (LinkedIn Profile)
• Dolca Thomas, Chief Medical Officer, EVP-Research & Development

What is Geoffrey A. Rotstein's approval rating as Equillium's CEO?

7 employees have rated Equillium CEO Geoffrey A. Rotstein on Glassdoor.com. Geoffrey A. Rotstein has an approval rating of 50% among Equillium's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Equillium's key competitors?

Some companies that are related to Equillium include Inventiva (IVA), Arbutus Biopharma (ABUS), ANI Pharmaceuticals (ANIP), PyroGenesis Canada (PYR), Chimerix (CMRX), Pliant Therapeutics (PLRX), Karyopharm Therapeutics (KPTI), Veru (VERU), Pharming Group (PHAR), ESSA Pharma (EPIX), Nkarta (NKTX), Rhythm Pharmaceuticals (RYTM), Ocular Therapeutix (OCUL), Theseus Pharmaceuticals (THRX) and Omeros (OMER).
View all of EQ's competitors.

When did Equillium IPO?

(EQ) raised $70 million in an initial public offering on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.

What is Equillium's stock symbol?

Equillium trades on the NASDAQ under the ticker symbol "EQ."

Who are Equillium's major shareholders?

Equillium's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (10.79%), Geode Capital Management LLC (0.52%), Two Sigma Securities LLC (0.29%), Citadel Advisors LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Equillium stock include Jason A Keyes, Jason A Keyes and Stephen Connelly.
View institutional ownership trends for Equillium.

Which major investors are buying Equillium stock?

EQ stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Two Sigma Securities LLC, Citadel Advisors LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Equillium or or view top insider-buying stocks.

How do I buy shares of Equillium?

Shares of EQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Equillium's stock price today?

One share of EQ stock can currently be purchased for approximately $4.94.

How much money does Equillium make?

Equillium has a market capitalization of $145.19 million. The company earns $-29.81 million in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does Equillium have?

Equillium employs 31 workers across the globe.

What is Equillium's official website?

The official website for Equillium is equilliumbio.com.

Where are Equillium's headquarters?

Equillium is headquartered at 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037.

How can I contact Equillium?

Equillium's mailing address is 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037. The company can be reached via phone at (858) 412-5302 or via email at [email protected].